CAR T in Practice: What Oncologists Need to Know With Ehsan Malek, MD

Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation